MaxCyte Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . MaxCyte
MXCT Stock  USD 1.50  0.05  3.23%   
Analyzing historical trends in various income statement and balance sheet accounts from MaxCyte's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting MaxCyte's valuation are summarized below:
Gross Profit
27.5 M
Profit Margin
(1.33)
Market Capitalization
165.3 M
Enterprise Value Revenue
2.2597
Revenue
34.4 M
There are currently one hundred twenty fundamental ratios for MaxCyte that can be evaluated and compared over time across peers in the industry. All traders should check MaxCyte's last-minute fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 720.2 M in 2026. Enterprise Value is likely to gain to about 696.4 M in 2026

MaxCyte Total Revenue

23.45 Million

Check MaxCyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MaxCyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.8 M, Interest Expense of 138.6 K or Selling General Administrative of 35.9 M, as well as many indicators such as Price To Sales Ratio of 12.34, Dividend Yield of 0.0 or PTB Ratio of 2.0. MaxCyte financial statements analysis is a perfect complement when working with MaxCyte Valuation or Volatility modules.
  
Build AI portfolio with MaxCyte Stock
Check out the analysis of MaxCyte Correlation against competitors.
For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.

MaxCyte Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets289.2 M275.4 M107.1 M
Slightly volatile
Short and Long Term Debt Total21.8 M20.7 M8.7 M
Slightly volatile
Total Current Liabilities10.3 M18.1 M9.2 M
Slightly volatile
Property Plant And Equipment Net36.8 M35 M11.8 M
Slightly volatile
Current Deferred Revenue3.7 M6 M3.2 M
Slightly volatile
Accounts Payable1.5 M1.2 M1.7 M
Very volatile
Cash18.9 M32.1 M16.3 M
Slightly volatile
Non Current Assets Total81.9 M78 M21.8 M
Slightly volatile
Cash And Short Term Investments186.5 M177.7 M75.5 M
Slightly volatile
Net Receivables4.4 M5.4 M3.7 M
Slightly volatile
Common Stock Shares Outstanding66.9 M120.6 M62.7 M
Slightly volatile
Liabilities And Stockholders Equity289.2 M275.4 M107.1 M
Slightly volatile
Non Current Liabilities Total21.1 M20.1 M8.1 M
Slightly volatile
Inventory10.8 M10.3 M4.3 M
Slightly volatile
Other Current Assets4.4 M4.1 M1.8 M
Slightly volatile
Total Liabilities40.1 M38.2 M17.8 M
Slightly volatile
Total Current Assets207.3 M197.4 M85.3 M
Slightly volatile
Short Term Debt781.2 K777.6 K1 M
Slightly volatile
Common Stock1.3 M1.2 M557.1 K
Slightly volatile
Other Liabilities1.6 M1.5 M702.9 K
Slightly volatile
Net Tangible Assets306.7 M292.1 M108.2 M
Slightly volatile
Long Term Debt5.2 M5.7 M4.6 M
Slightly volatile
Common Stock Total Equity807.8 K1.2 M706 K
Slightly volatile
Net Invested Capital144.9 M237.2 M94.6 M
Slightly volatile
Property Plant And Equipment Gross53.2 M50.7 M14.4 M
Slightly volatile
Short and Long Term Debt680.7 K765.8 K835.9 K
Slightly volatile
Non Current Liabilities Other557.6 K315.1 K448.2 K
Pretty Stable
Net Working Capital124.8 M179.3 M80.9 M
Slightly volatile
Property Plant Equipment28.6 M27.3 M9.5 M
Slightly volatile
Short Term Investments108.8 M145.6 M57.2 M
Slightly volatile
Capital Stock941.9 K1.2 M721.1 K
Slightly volatile
Other Assets976.9 K930.4 K295.5 K
Slightly volatile
Capital Surpluse421.9 M449.4 M385.8 M
Slightly volatile

MaxCyte Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization5.8 M5.5 M1.6 M
Slightly volatile
Interest Expense138.6 K145.9 K394 K
Very volatile
Selling General Administrative35.9 M34.1 M12.6 M
Slightly volatile
Selling And Marketing Expenses32.2 M30.7 M11.5 M
Slightly volatile
Total Revenue23.4 M44.4 M20.9 M
Slightly volatile
Gross Profit20.6 M36.3 M18.1 M
Slightly volatile
Other Operating Expenses108.5 M103.3 M41 M
Slightly volatile
Research Development13 M25.6 M11.6 M
Slightly volatile
Cost Of Revenue8.6 M8.2 M3.1 M
Slightly volatile
Total Operating Expenses99.9 M95.1 M37.9 M
Slightly volatile
Reconciled Depreciation5.8 M5.5 M1.6 M
Slightly volatile
Interest Income12.2 M11.7 M2.9 M
Slightly volatile

MaxCyte Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation15.8 M15 M4.9 M
Slightly volatile
Begin Period Cash Flow56.2 M53.5 M18.3 M
Slightly volatile
Depreciation5.2 M5 M1.5 M
Slightly volatile
Capital Expenditures2.8 M1.9 M2.2 M
Slightly volatile
End Period Cash Flow18.9 M32.1 M16.3 M
Slightly volatile
Change To Netincome14.4 M13.7 M4.9 M
Slightly volatile
Change To Liabilities751.1 K790.6 K1 M
Pretty Stable
Sale Purchase Of Stock392.4 K413.1 K169.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12.3412.9956.7336
Slightly volatile
Days Sales Outstanding53.2639.8261.658
Pretty Stable
Stock Based Compensation To Revenue0.320.30.1301
Slightly volatile
Capex To Depreciation0.330.341.6129
Pretty Stable
EV To Sales12.0612.6956.4439
Slightly volatile
Inventory Turnover0.960.920.969
Slightly volatile
Days Of Inventory On Hand375412432
Slightly volatile
Payables Turnover2.494.712.8999
Slightly volatile
Sales General And Administrative To Revenue0.730.690.4546
Slightly volatile
Research And Ddevelopement To Revenue0.420.520.5088
Slightly volatile
Capex To Revenue0.05820.03850.0618
Slightly volatile
Cash Per Share0.811.330.9041
Slightly volatile
Days Payables Outstanding76.2780.28375
Slightly volatile
Income Quality0.80.770.7792
Slightly volatile
Current Ratio10.289.795.7494
Slightly volatile
Receivables Turnover6.559.496.4536
Pretty Stable
Capex Per Share0.01350.01420.0306
Pretty Stable
Revenue Per Share0.850.420.6776
Pretty Stable
Interest Debt Per Share0.190.20.3931
Pretty Stable
Debt To Assets0.08230.08660.335
Slightly volatile
Operating Cycle428452493
Slightly volatile
Days Of Payables Outstanding76.2780.28375
Slightly volatile
Ebt Per Ebit1.230.921.0984
Slightly volatile
Total Debt To Capitalization0.08780.09250.9568
Slightly volatile
Quick Ratio9.759.295.4098
Slightly volatile
Cash Ratio1.261.591.4265
Slightly volatile
Days Of Inventory Outstanding375412432
Slightly volatile
Days Of Sales Outstanding53.2639.8261.658
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.990.951.1822
Pretty Stable
Fixed Asset Turnover1.381.4616.0852
Slightly volatile
Debt Ratio0.08230.08660.335
Slightly volatile
Price Sales Ratio12.3412.9956.7336
Slightly volatile
Asset Turnover0.180.190.8663
Slightly volatile
Gross Profit Margin0.970.940.8818
Slightly volatile

MaxCyte Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap720.2 M558.2 M816.8 M
Slightly volatile
Enterprise Value696.4 M526.2 M780.8 M
Slightly volatile

MaxCyte Fundamental Market Drivers

MaxCyte Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About MaxCyte Financial Statements

MaxCyte shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although MaxCyte investors may analyze each financial statement separately, they are all interrelated. The changes in MaxCyte's assets and liabilities, for example, are also reflected in the revenues and expenses on on MaxCyte's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue6 M3.7 M
Total Revenue44.4 M23.4 M
Cost Of Revenue8.2 M8.6 M
Stock Based Compensation To Revenue 0.30  0.32 
Sales General And Administrative To Revenue 0.69  0.73 
Research And Ddevelopement To Revenue 0.52  0.42 
Capex To Revenue 0.04  0.06 
Revenue Per Share 0.42  0.85 
Ebit Per Revenue(1.52)(1.45)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for MaxCyte Stock Analysis

When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY